Advertisement
Screener

Verrica Pharmaceuticals Inc. (VRCA) Graph

VRCA Revenue Flow

Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

  • 2026-06-30: Revenue $5.86M; Cost of revenue (m); Research and development $6.03M; Selling, general and administrative $10.35M.
  • 2026-03-31: Revenue $5.02M; Cost of revenue (m); Research and development $3.86M; Selling, general and administrative $9.99M.
  • 2025-12-31: Revenue $5.09M*; Cost of revenue (m); Research and development $2.52M*; Selling, general and administrative $8.12M*.
  • 2025-09-30: Revenue $14.34M; Cost of revenue (m); Research and development $2.21M; Selling, general and administrative $9.40M.

Product or service

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

VRCA revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.Product$5.09MLicense And CollaborationRevenue Milestones$0.00Revenue$5.86MOperating expenses$18.96MOperating income-$13.10MOther income, net-$3.00KResearch & development$6.03MSelling, general& administrative$10.35MNet income-$13.15M

Segment

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

VRCA revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.Reportable Segment$5.86MRevenue$5.86MOperating expenses$18.96MOperating income-$13.10MOther income, net-$3.00KResearch & development$6.03MSelling, general& administrative$10.35MNet income-$13.15M

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueCost of revenueResearch and developmentSelling, general and administrativeOperating expensesNet income
2026-06-30$5.86M(m)$6.03M$10.35M$18.96M-$13.15M
2026-03-31$5.02M(m)$3.86M$9.99M$14.74M-$9.68M
2025-12-31$5.09M*(m)$2.52M*$8.12M*$12.28M*-$8.09M*
2025-09-30$14.34M(m)$2.21M$9.40M$12.72M-$274.00K
2025-06-30$12.70M(m)$1.85M$8.85M$11.19M$204.00K
2025-03-31$3.44M$700.00K$2.28M$8.85M$11.57M-$9.74M
2024-12-31(m)$800.00K*(m)(m)(m)(m)
2024-09-30-$1.78M$400.00K$2.40M$16.08M$18.92M-$22.86M
2024-06-30$5.18M$700.00K$3.32M$16.52M$20.38M-$17.19M
2024-03-31$3.83M$700.00K$4.95M$16.34M$22.43M-$20.33M
2023-09-30$2.92M$300.00K$6.51M$20.05M$26.83M-$24.80M
2023-06-30$182.00K(m)$5.72M$5.94M$11.80M-$10.99M
2023-03-31$37.00K(m)$2.74M$4.32M$7.13M-$6.59M
2022-09-30$8.32M(m)$2.78M$3.92M$6.87M$83.00K
2022-06-30$214.00K(m)$3.94M(m)$9.34M-$10.17M
2022-03-31$431.00K(m)$2.44M(m)$7.84M-$8.47M
2021-09-30$0.00(m)$3.76M(m)$11.77M-$12.83M
2021-06-30$0.00(m)$3.45M(m)$10.73M-$11.78M
2021-03-31$12.00M(m)$5.36M(m)$11.94M-$936.00K
2020-09-30(m)(m)$4.99M(m)$9.64M-$10.49M
2020-06-30(m)(m)$3.52M(m)$8.63M-$9.41M
2020-03-31(m)(m)$4.89M(m)$9.88M-$9.82M
2019-12-31(m)(m)$3.97M(m)$7.99M-$7.64M
2019-09-30(m)(m)$3.05M(m)$6.54M-$6.09M
2019-06-30(m)(m)$3.93M(m)$7.52M-$7.00M
2019-03-31(m)(m)$4.49M(m)$8.03M-$7.48M
2018-12-31(m)(m)$4.92M(m)$8.19M-$7.58M
2018-09-30(m)(m)$3.47M(m)$6.33M-$5.91M
2018-06-30(m)(m)$3.52M(m)$5.47M-$5.32M
2018-03-31(m)(m)$927.00K(m)$1.89M-$1.85M
2017-12-31(m)(m)$1.12M(m)$1.43M-$1.44M
2017-09-30(m)(m)$1.12M(m)$1.36M-$1.36M
2017-06-30(m)(m)$977.00K(m)$1.09M-$1.09M
2017-03-31(m)(m)$515.00K(m)$570.00K-$570.00K

Revenue and expense 6 month

Period endRevenueCost of revenueResearch and developmentSelling, general and administrativeOperating expensesNet income
2026-06-30$10.88M(m)$9.89M$20.34M$33.70M-$22.84M
2025-06-30$16.14M(m)$4.13M$17.70M$22.76M-$9.54M
2024-06-30$9.00M$1.40M$8.27M$32.86M$42.81M-$37.52M
2023-06-30$219.00K(m)$8.46M$10.26M$18.92M-$17.58M
2022-06-30$645.00K(m)$6.39M(m)$17.18M-$18.64M
2021-06-30$12.00M(m)$8.81M(m)$22.67M-$12.71M
2020-06-30(m)(m)$8.41M(m)$18.51M-$19.23M
2019-06-30(m)(m)$8.41M(m)$15.55M-$14.48M
2018-06-30(m)(m)$4.44M(m)$7.36M-$7.16M
2017-06-30(m)(m)$1.49M(m)$1.67M-$1.67M

Revenue and expense 9 month

Period endRevenueCost of revenueResearch and developmentSelling, general and administrativeOperating expensesNet income
2025-09-30$30.48M(m)$6.33M$27.10M$35.48M-$9.81M
2024-09-30$7.22M$1.80M$10.67M$48.94M$61.73M-$60.38M
2023-09-30$3.14M$300.00K$14.97M$30.31M$45.76M-$42.38M
2022-09-30$8.96M(m)$9.17M$14.22M$24.05M-$18.55M
2021-09-30$12.00M(m)$12.57M(m)$34.44M-$25.54M
2020-09-30(m)(m)$13.40M(m)$28.15M-$29.72M
2019-09-30(m)(m)$11.46M(m)$22.09M-$20.57M
2018-09-30(m)(m)$7.91M(m)$13.69M-$13.07M
2017-09-30(m)(m)$2.61M(m)$3.02M-$3.02M

Revenue and expense 12 month

Period endRevenueCost of revenueResearch and developmentSelling, general and administrativeOperating expensesIncome taxNet income
2025-12-31$35.58M(m)$8.86M$35.22M$47.76M$0.00-$17.90M
2024-12-31$7.57M$2.60M$11.84M$58.82M$73.48M$0.00-$76.60M
2023-12-31$5.12M$500.00K$20.30M$47.30M$70.88M$0.00-$67.00M
2022-12-31$9.03M(m)$12.20M$17.41M$30.33M$0.00-$24.49M
2021-12-31$12.00M(m)$15.93M(m)$42.91M(m)-$35.08M
2020-12-31(m)(m)$15.67M(m)$40.18M(m)-$42.69M
2019-12-31(m)(m)$15.44M(m)$30.08M(m)-$28.21M
2018-12-31(m)(m)$12.83M(m)$21.88M(m)-$20.65M
2017-12-31(m)(m)$3.73M(m)$4.46M(m)-$4.46M

Similar stocks

Stock NameCountryMarket CapPE Ratio
OS Therapies Inc (OSTX)United States$0.076B-2.17
iBio, Inc. (IBIO)United States$0.077B-2.94
MAIA Biotechnology, Inc. (MAIA)United States$0.077B-2.30
Valion Bio, Inc. (VBIO)United States$0.077B
Adicet Bio, Inc. (ACET)United States$0.078B-0.81
Lifevantage Corp (LFVN)United States$0.078B15.40
Aldeyra Therapeutics, Inc. (ALDX)United States$0.074B-5.57
Cingulate Inc. (CING)United States$0.073B-2.64
Spero Therapeutics, Inc. (SPRO)United States$0.073B17.41
Gain Therapeutics, Inc. (GANX)United States$0.080B-4.40